Figure 7.

VEGFR2 expression ex vivo significantly decreased in G55 glioma tissue in anti-ELTD1 Ab treated mice. SA-HRP staining of the VEGFR2 probe (via the biotin moiety) in untreated G55 tumors (A), compared to anti-ELTD1 Ab treated glioma tissue (B). (C) Percent positivity for the VEGFR2 probe was significantly reduced in anti-VEGFR2 Ab-treated gliomas, compared to untreated tumors (P < 0.05). Mean ± SD, n = 4.